Neurogene (NGNE) Expected to Announce Earnings on Friday

Key Points

• Neurogene is set to announce its Q2 2025 earnings results on August 8th, expecting to report losses of ($1.15) per share.
• The company's stock has seen a significant decline of 44%, and analysts project a consensus price target of $46.17 with a rating of "Moderate Buy".
• Insider transactions reveal that Stuart Cobb sold nearly 7,000 shares recently, indicating a 24.63% decrease in his position.

Neurogene (NASDAQ:NGNE - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter.

Neurogene (NASDAQ:NGNE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.03). On average, analysts expect Neurogene to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Neurogene Stock Down 0.2%

NGNE stock traded down $0.05 during midday trading on Monday, hitting $21.73. The company's stock had a trading volume of 10,483 shares, compared to its average volume of 236,451. The stock's 50-day moving average price is $20.02 and its 200 day moving average price is $16.95. Neurogene has a 1 year low of $6.88 and a 1 year high of $74.49. The stock has a market cap of $309.87 million, a price-to-earnings ratio of -5.01 and a beta of 1.69.

Insider Activity at Neurogene

In other news, insider Stuart Cobb sold 6,797 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $15.15, for a total transaction of $102,974.55. Following the transaction, the insider directly owned 20,794 shares in the company, valued at approximately $315,029.10. This represents a 24.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.92% of the company's stock.

Hedge Funds Weigh In On Neurogene

An institutional investor recently raised its position in Neurogene stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 17.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,983 shares of the company's stock after acquiring an additional 1,059 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Neurogene were worth $82,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 52.37% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Craig Hallum assumed coverage on Neurogene in a research report on Tuesday, June 17th. They set a "buy" rating and a $50.00 price target on the stock. BMO Capital Markets reaffirmed an "outperform" rating and set a $26.00 price target (up previously from $22.00) on shares of Neurogene in a research report on Thursday, June 12th. HC Wainwright dropped their price target on Neurogene from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Robert W. Baird cut Neurogene from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $38.00 to $24.00 in a research report on Friday, May 16th. Finally, Baird R W cut Neurogene from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.17.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.